Leonard Gomella, chair of the urology department and director of the Kimmel Cancer Center Network, explains active surveillance when it comes to a prostate cancer diagnosis.
Leonard Gomella, chair of the urology department and director of the Kimmel Cancer Center Network at Jefferson University Hospitals, explains active surveillance when it comes to a prostate cancer diagnosis.
"Not all patients with prostate cancer require aggressive treatment," he says. "If, in meeting with your doctor, they discuss with you active surveillance versus actively treating the tumor, they need to really explain to you what active surveillance is. It's not that they're ignoring you, but it's keeping an eye on the cancer."
Active surveillance may be different for each practice, but "in general, it's a PSA (prostate-specific antigen test) and a rectal exam about every six month, and every year or two a biopsy of the prostate," he says.
Novel Drug Granted FDA Fast Track in Rare Prostate Cancer Subset
February 13th 2024The Food and Drug Administration has granted a Fast Track designation to the novel immune activator drug BXCL701 in combination with a checkpoint inhibitor for patients with metastatic small cell neuroendocrine prostate cancer (SCNC).
Read More